Bacteraemia due to Escherichia coli producing extended-spectrum beta-lactamases (ESBL): Clinical relevance and today's' insights;Bacteriemias por Escherichia coli productor de betalactamasas de espectro extendido (BLEE): Significación clínica y perspectivas actuales

Revista Espanola de Quimioterapia

Volumn 24, Issue 2, 2011, Pages 57-66

  García Hernández, Ana Ma ^a   García Vázquez, Elisa ^a,b   Hernández Torres, Alicia ^a   Ruiz, Joaquín ^a   Yagüe, Genoveva ^a   Herrero, José Antonio ^a,b   Gómez, Joaquín ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Bacteraemia; ESBL; Escherichia coli; Extended spectrum beta Lactamases

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE CTX M; EXTENDED SPECTRUM BETA LACTAMASE; ANTIINFECTIVE AGENT; BETA LACTAMASE; ESCHERICHIA COLI PROTEIN;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MORTALITY; NONHUMAN; PRESCRIPTION; REVIEW; BACTEREMIA; CLASSIFICATION; DISK DIFFUSION; ENZYME SPECIFICITY; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY; MULTICENTER STUDY (TOPIC); PATHOGENICITY; PHYSIOLOGY; RISK FACTOR; SPAIN; VIRULENCE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DISK DIFFUSION ANTIMICROBIAL TESTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; KLEBSIELLA PNEUMONIAE; MULTICENTER STUDIES AS TOPIC; RISK FACTORS; SPAIN; SUBSTRATE SPECIFICITY; VIRULENCE;

EID: 80054025888     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. a ed 2006:27-36.
2. Bush K. Characterization of betalactamases. Antimicrob Agents Chemother 1989;33:259-63.
3. Campos J, Baquero F. Resistencia a antibióticos: ¿qué hacer ahora? Med Clin 2002;119:656-8.
4. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 2005;36:697-705.
5. Jacoby GA. Broad-Spectrum transmissible beta-lactamases. N Engl J Med 1988;319:723-4.
6. Paterson DL, Bonomo RA. Extended-spectrum B-lactamases: a Clinical Update. J Clin Microbiol Rev 2005;18:657-86.
7. Gobernado M. Betalactamasas de espectro extendido en aumento. Rev Esp Quimioterap 2005;18:115-7.
8. Rodríguez-Baño J, Pascual A. Clinical significance of extendedspectrum beta-lactamases. Expert Rev Anti Infect Ther 2008; 6: 671-83.
9. Peralta G, Sánchez MB, Garrido JC, De Benito I, Cano ME, Martínez-Martínez L et al. Impact of antibiotic resistance and adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60: 855-63.
10. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007;55:254-9.
11. Schwaber M, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase producing Enterobacteriaceae. Antimicrob Agents Chemother 2006;50:1257-62.
12. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38:1279-86.
13. Martínez-Martínez L, Calvo J. The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria: current situation. Enferm Infecc Microbiol Clin 2010;Suppl 2:25-31.
14. Angel Díaz M, Ramón Hernández J, Martínez Martínez L, Rodríguez-Baño J, Pascual A. Extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006). Enferm Infecc Microbiol Clin 2009;27:503-10.
15. Rodríguez-Baño J, Alcalá J, Cisneros JM, Grill F, Oliver A, Horcajada JP. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother 2009;63:781-4.
16. Pitout JDD, Gregson DB, Campbell L, Laupland KB. Molecular Characteristics of Extended-Spectrum-B-Lactamase-Producing Escherichia coli Isolates Causinmg Bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of Clone ST131 as a cause of Community-Acquired Infections. Antimicrob Agents Chemother 2009;53:2846-51.
17. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum betalactamase-producing Enterobacteriaceae during non-outbreak situations in Spain. J Clin Microbiol 2004;42:4769-75.
18. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP et al. Health care-associated blood-stream infections in adults: a reason to change the accepted definitions of community-acquired bacteremia. Ann Intern Med 2002;137:791-7.
19. Wisplinghoff H, Bischoff T, Talent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide study. Clin Infect Dis 2004;39:309-17.
20. Ortega M, Marco F, Soriano A, Almela M, Martínez A, Muñoz A. Analysis of 4.758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistenat strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568-74.
21. Cantón R, Valdezate S, Mir N. Resistencia a los antimicrobianos. En (García-Sánchez J. E, López R, Prieto J., Eds.). Antimicrobianos en medicina. Sociedad Española de Quimioterapia. Prous Science Ed. 1999: 41-7.
22. Cantón R. Prevalence and spread of extended-spectrum betalactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008;14 (Suppl 1):S144-S153.
23. Alpuche Aranda C. Infecciones nosocomiales por bacterias resistentes a cefalosporinas de espectro extendido: asociación de dos peligrosos enemigos. Enferm Infecc Microbiol Clin 2002;22: 192-9.
24. Muñoz Bellido J.L. Betalactamasas de espectro ampliado: ¿son hoy un serio problema en España? Rev Esp Quimioterap 2004;17:314-6.
25. Bush K. Alarming 2-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 2010;13:558-64.
26. Giamarellou H. Multidrug resistance in Gram-negative Bacteria that Produce Extended-Spectrum Beta-Lactamases (ESBLs). Clin Microbiol Infect 2005;11:1-16.
27. Diestra K, Coque TM, Miró E, Oteo J, Nicolau CJ, Campos J, et al; Red Española de Investigación en Patología Infecciosa. Caracte-rización y epidemiología molecular de betalactamasas de espectro extendido en Escherichia coli y Klebsiella pneumoniae en 11 hospitales españoles (2004). Enferm Infecc Microbiol Clin 2008;26:404-10.
28. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005;56:451-4.
29. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-74.
30. Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori F. Bloodstream infections caused by extended-spectrum-betalactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008;52:3244-52.
31. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase and AmpCproducing Enterobacteriaceae from the MYSTIC Program in Europe and the United States. Diagn Microbiol Infect Dis 2995;5:257-64.
32. Warren RE, Ensor VM, O'Neill P, Butler V, Taylor J, Nye K, et al. Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2008;61:504-8.
33. Smet A, Martel A, Persoons D, Dewulf J, Heyndrickx M, Catry B, et al. Diversity of extended-spectrum beta-lactamases and class C beta-lactamases among cloacal Escherichia coli Isolates in Belgian broiler farms. Antimicrob Agents Chemother 2008;52:1238-43.
34. Lavilla S, González-López JJ, Miró E, Domínguez A, Llagostera M, Bartolomé RM, et al. Dissemination of extended-spectrum betalactamase-producing bacteria: the food-borne outbreak lesson. J Antimicrob Chemother 2008;61:1244-51.
35. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum ß-lactamase phenotype and characterization of isolates from Europe, the American and the Western Pacific Region. Clin Infect Dis 2001;32(Suppl 2):S94-S103.
36. Disponible en http://www.lahey.org/studies. Datos recopilados el 18/08/2009.
37. EARSS data. Disponible en http://www.earss.rivm.nl. Datos recopilados el 13/10/2009.
38. Hernández JR, Pascual A, Cantón R, Martínez-Martínez L. Escherichia coli y Klebsiella pneumoniae productores de ß-lactamasas de espectro extendido en hospitales españoles (Proyecto GEIHBLEE 2000). Enferm Infecc Microbiol Clin 2003;21:77-82.
39. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pascual A. Epidemiology end clinical features of infections caused by extended. spectrum ß-lactamaseproducing Escherichia coli in non hospitalized patients. J Clin Microbiol 2004;42:1089-94.
40. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruiz M, Peña C. Community-onset bacteremia due to extended-spectrum-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010;50:40-8.
41. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing Extended-spectrum ß-lactamases: a case control study of risk factors and outcomes. Scand J Infect Dis 2002;34:567-73.
42. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP et al. Community infections caused by extendedspectrum ß-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897-902.
43. Ramphal R, Ambrose PG. Extended-Spectrum ß-lactamases and clinical outcomes: current data. Clin Infect Dis 2006:42(Suppl 4):S164-S172.
44. Du B, Long Y, Liu H, Chen D, Liu D, Xu Y. Extended-spectrum ßlactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002;28:1718-23.
45. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori R. et al. Predictors of mortality in patiens with bloodstream infections caused by extended-spectrum-ßlactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:1987-94.
46. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23:320-6.
47. Oteo J. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother 2002;50:945-52.
48. Bush K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 2010;14:224.
49. Craig WA, Bhavnani SM, Ambrose PG. The inoculum effect: fact or artifact?. Diagn Microbiol Infect Dis 2004;50:229-30.
50. Vila J, Marco F. Interpretive reading of the non-fermenting gram-negative bacilli antibiogram. Enferm Infecc Microbiol Clin 2010;28:726-36.
51. Wong-Beringer A. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135-46.
52. Lye DC, Wijaya L, Chang J, Teng CP, Leo YS. Ertapenem for treatment of extended-spectrum ß-lactamase-producing and multidrug-resistant gram-negative bacteraemia. Ann Acad Med Singapore 2008;37:831-4.
53. Elliott E, Brink AJ, Van Greune J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in patient with pneumonia caused by Klebsiella pneumoniae with an extendedspectrum ß-lactamase. Clin Infect Dis 2006;42:95-8.
54. Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumanii. J Clin Microbiol 2000;38:4086-95.
55. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010;300:371-9.
56. Thomson KS. Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues. J Clin Microbiol 2010;48:1019-25.
57. Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sacer HS. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum ß-lactams. Braz J Infect Dis 2000;4:226-35.
58. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam and the inoculum effect in tests with extended-spectrum ß-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.
59. Oliver A, Cantón R. Enterobacterias productoras de beta-lactamasas plasmídicas de espectro extendido. Disponible en: http://www.seimc.org/control/revi_Bacte/Blees.htm.
60. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman N. Epidemiological investigation of fluoroquinolone-resistance in infections due to extended-spectrum ß-lactamaseproducing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288-94.
61. Sánchez Artola B. Betalactamasas de espectro extendido (BLEE). Revista Electrónica de Medicina Intensiva 2004;4:Art C6
62. Lavigne JP, Bonnet R, Michaux-Charachon S, Jourdan J, Caillon J, Sotto A. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamse-producing Gram-negative bacteria. J Antimicrob Chemother 2004;53:616-9.
63. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR et al. Colistin: the re-emerging intibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
64. De Cueto M, Hernández JR, López-cerero L, Morillo C, Pascual A. Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de beta-lactamasas de espectro extendido. Enferm Infecc Microbiol Clin 2006;24:613-6.
65. Pullucku H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomicyn in the treatment of extended-sectrum beta-lactamase-producing Escherichia coli related uninary tract infections. Int J Antimicrob Agents 2007;29:62-5.
66. Warren RE, Harvey G, Carr R, Ward D, Doroshenko A. Control of infections due to extended. spectrum-lactamase-producing organisms in hospitals and the community. Clin Microbiol Infect 2008;14(Suppl 1):124-33.
67. Rodriguez-Baño J, Navarro MD, Romero L, Muniain MA, Perea EJ, Pérez-Cano R et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006;42:37-45.
68. Fridkin SK. Routine cycling of antimicrobial agents as an infection control measure. Clin Infect Dis 2003;36:1438-44.